Chronic cerebrovascular diseases: pathogenetic management
https://doi.org/10.21518/2079-701X-2016-8-68-75
Abstract
The article considers the key issues of the clinical pattern, diagnosis and treatment of chronic cerebral ischemia. The results of the observation program "Thiocetam for focal neurological, mild cognitive, asthenic and emotional disorders accompanying chronic organic disease of the central nervous system - discirculatory encephalopathy." The article demonstrates that Thiocetam has a beneficial effect against mild cognitive impairment, asthenic disorders, light and moderate emotional disorders in the studied population.
About the Authors
I. A. Schukin
Russian National Research Medical University named after N.I. Pirogov
Russian Federation
Russian Federation
A. V. Lebedeva
Russian National Research Medical University named after N.I. Pirogov
Russian Federation
Russian Federation
M. S. Fidler
Russian National Research Medical University named after N.I. Pirogov
Russian Federation
Russian Federation
References
1. Сборник среднемосковских показателей деятельности медицинских организаций ДЗМ за 2013-2014 гг.
2. Никифоров А.С., Гусев Е.И. Частная неврология. М.: «ГОЭТАР-Медиа», 2008, 24.
3. Burns A, I Liffe S. Alzheimer's disease. BMJ, 2009, 338.
4. Peuvot J, Schank A, DeLeers M, Brasseur R. Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis. Biochem Pharmacol, 1995, 50: 1129-1134.
5. FassouLaki A, Kostopanagiotou G, Kaniaris P Varonos DD. Piracetam attenuates the changes in the surface potentiaL of the phosphatidyLcho-Line monolayer produced by alcohols. Acta Anaesthesiol Belg, 1985, 36: 47-51.
6. MuLLer WE, Koch S, Scheuer K, Rostock A, Bartsch R. Effects of piracetam on membrane fLuidity in the aged mouse, rat and human brain. Biochem Pharmacol, 1997, 53:135-140.
7. Moriau M, Crasborn L, Lavenne-Pardonge E, Von FrenckeLL R, CoL-Debeys C. PLateLet anti-aggre-gant and rheoLogicaL properties of piracetam. Arzneimittelforschung, 1993, 43: 110-118.
8. Eckert GP, Cairns NJ, MuLLer WE. Piracetam reverses hippocampaL membrane aLterations in ALzheimer's disease. J Neural Transm, 1999, 106: 757-761.
9. MuLLer WE, Eckert GP, Eckert A. Piracetam: NoveLty in a unique mode of action. Pharmacopsychiatry, 1999, 32 (1): 2-9.
10. MuLLer WE. Age reLated quantitative and quaLitative receptor changes and pharmacoLogicaL reactivity. In: Racagni G, MendLewicz J, Eds. Treatment of age-reLated cognitive dysfunction: PharmacoLogicaL and cLinicaL evaLuation. Int Acad Biomed Drug Res. BaseL: Karger 1992, 2: 35-40.
11. VaLzeLLi L, Bernasconi S, SaLa A. Piracetam activity may differ according to the age of the recipient mouse. Int Pharmacopsychiatry, 1980, 15: 150-156.
12. OLpe H-R, Steinmann MW. The activating action of vincamine, piracetam and hydergine on the activity of the noradrenergic neurons of the Locus coeruLeus. Behav Neural Biol, 1981, 33: 249-251.
13. Cohen SA, MuLLer WE. Effects of piracetam on N-methyL-D-aspartate receptor properties in the aged mouse brain. Pharmacology, 1993, 47: 217-222.
14. PiLch H, MuLLer WE. Piracetam eLevates musca-rinic choLinergic receptor density in the fronta! cortex of aged but not of young mice. Psychopharmacology, 1988, 94: 74-78.
15. Cohen SA, MuLLer WE. Effects of piracetam on N-methyL-D-aspartate receptor properties in the aged mouse brain. Pharmacology, 1993, 47: 217-222.
16. Brandao F, Cadete-Leite A, Andrade JP, Madeira MD, PauLa-Barbosa MM. Piracetam promotes mossy fiber synaptic reorganization in rats withdrawn from aLcohoL. Alcohol, 1996, 13: 239-249.
17. Mondadori C, Schmutz M. Synergistic effects of oxiracetam and piracetam in combination with antiepiLeptic drugs. Acta Neurol Scand 1986, 74(SuppL 109): 113-116
18. PauLa-Barbosa MM, Brandao F, Pinho MC, Andrade JP, Madeira MD, Cadete-Leite A. The effects of piracetam on Lipofuscin of the rat cer-ebeLLar and hippocampaL neurons after Long-term aLcohoL treatment and withdrawaL: A quantitative study. Alcohol Clin Exp Res, 1991, 15: 834-838.
19. Moriau M, Crasborn L, Lavenne-Pardonge E, Von FrenckeLL R, CoL-Debeys C. PLateLet anti-aggre-gant and rheoLogicaL properties of piracetam. Arzneimittelforschung, 1993, 43: 110-118.
20. Reuse-BLom S. MicrocircuLation of the piaL vesseLs in the rabbit. Acta Cardiol, 1979, 34: 35-36.
21. Herrschaft H. The effect of piracetam on gLobaL and regionaL cerebraL bLood fLow in acute cerebraL ischemia of man. Med Klin, 1978,73:195202.
22. Sato M, Heiss WD. Effect of piracetam on cerebraL bLood fLow and somatosensory evoked potentiaL during normotension and hypotensive ischemia in cats. Arzneimittelforschung, 1985, 35:790-792.
23. Waegemans T, WiLsher CR, Danniau A, Ferris SH, Kurz A, WinbLad B. CLinicaL efficacy of piracetam in cognitive impairment: A meta-anaLysis. Dement Geriatr Cogn Disord, 2002, 13:217-224.
24. Сапеган Й.Д. Зкспер. и клин. фармакол. 2002. 2. 35-37.
25. Тиотриазолин И.А., Мазур Н.А., Волошин И.С. и др. Львов: Наутилус, 2005. 156 с.
26. Бєленічев І.Ф., Стець В.Е, Мазур І.А. Експер. фізіол. та біохімія, 2002, 1: 7-11.
27. Бєленічев І.Ф., Кучеренко Л.І., Мазур І.А. Експер. фізіол. та біохімія, 2002, 12: 24-29.
28. Бєленічев І.Ф., Губський Ю.І., Левицький Є.Л. Совр. пробл. Токсикол, 2002, 3: 24-31.
29. Бєленічев І.Ф., Коваленко С.І., Дунаєв В.В. Ліки, 2002, 1: 25-30.
30. Визир А.Д. и соавторы. Тиотриазолин - создание, механизм действия, достижения и перспективы применения в медицине. Актуальні питання фармацевтичної та медичної науки та практики: зб. наук. ст. - Запорожье, 2002. - Вип.VIII.- С. 3-11.
31. Бибик, В.В., Болгов, Д.М. Тиотриазолин: фармакология и фармакотерапия. Укр. мед. Альманах, 2000, 4: 226-229.
32. В.В. Дунаев и соавторы. Фармако-биохимические аспекты противоишемического действия препарата тиотриазолин в условиях эксперимента. Актуальні питання фармацевтичної та медичної науки та практики: зб. наук. ст. - Запорожье, 2002. - Вип. VIII. - С. 73-81.
33. Болгов, Д.М. Вплив тіотриазоліну на перебігвільно радикальних реакцій у структурах мозку щурів з компресійною травмою. Ліки, 2001, 5-6: 18-23.
34. Дзяк Л.А., Сирко А.Г., Дозозависимая эффективность Тиоцетама в лечении дисциркуляторной энцефалопатии II стадии вследствие атеросклероза сосудов головного мозга. Международный неврологический журнал, 5(15), 2007.
35. Антонова Н.А., Чижова К.Е., Шоломов И.И., Применение препарата Тиоцетам у пациентов, пренесших инфаркт головного мозга в бассейне левой средней мозговой артерии. Неврологический вестник, 2014, XLVI, вып. 1: 86--88.
Review
For citations:
Schukin IA, Lebedeva AV, Fidler MS. Chronic cerebrovascular diseases: pathogenetic management. Meditsinskiy sovet = Medical Council. 2016;(8):68-75. (In Russ.) https://doi.org/10.21518/2079-701X-2016-8-68-75
Views:
688
Email this article 